A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine
Headache The Journal of Head and Face Pain2020Vol. 60(3), pp. 564–575
Citations Over TimeTop 10% of 2020 papers
Paul Winner, Marielle A. Kabbouche, Marcy Yonker, Veronica Wangsadipura, Arlene Lum, Mitchell F. Brin
Abstract
Although this study did not meet its efficacy endpoints, onabotulinumtoxinA was well tolerated in this adolescent population. Given previous data demonstrating the benefits of onabotulinumtoxinA in adults with CM, additional studies with design modifications, including adequate statistical power, to assess the efficacy of multiple treatment cycles of onabotulinumtoxinA for CM prevention in adolescents may be informative.
Related Papers
- → Migraine and Stripe-Induced Visual Discomfort(1989)190 cited
- → Seasonal and Meteorological Factors in Primary Headaches(1988)10 cited
- → Self‐awareness of migraine: interpreting the labels that headache sufferers apply to their headaches.(2003)9 cited
- → Clinical manifestations of migraine(2001)7 cited
- → Serum Concentrations of Propranolol and Migraine Prophylaxis(1984)10 cited